Research Summary

Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood Marrow and Transplant Clinic.

Nina received a bachelor’s degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine. She then completed a residency in internal medicine at Columbia University and a fellowship in hematology/oncology at University of Texas MD Anderson Cancer Center.

Nina’s areas of professional interest include the intersection of immunology and oncology and helping patients fight multiple myeloma by boosting their immune systems.

A clinical professor at UCSF, Dr. Shah belongs to the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. She speaks Bengali and Spanish.

Education

Harvard University, Cambridge, MA, BA, 6/1998, Psychology & Biology (Cognitive Neuroscience)
New York University School of Medicine, New York, NY, MD, 5/2002, Doctorate of Medicine
Columbia University Medical Center, New York, NY, Residency, 6/2005, Internal Medicine
Columbia University Medical Center, New York, NY Post-Doctoral Research Fellow, 6/2007, Immunology
The University of Texas MD Anderson Cancer Center, Hematology Oncology, 7/2010, Hematology/Oncology

Honors & Awards

  • 2001
    Alfred B. Kornblut Medical Scholarship, New York University School of Medicine
  • 2002
    Alpha Omega Alpha Medical Honor Society, New York University School of Medicine
  • 2002
    Augusta Landes Packer Award, New York University School of Medicine
  • 2002
    New York University School of Medicine Alumni Award, New York University School of Medicine
  • 2005-2007
    Empire Clinical Research Investigator Program Grant, Columbia University
  • 2008
    American Association for Cancer Research/American Society of Clinical Oncology Methods in Clinical Cancer Research Workshop, U. T. M. D. Anderson Cancer Center
  • 2008
    Clifton D. Howe Award for Clinical Excellence, U. T. M. D. Anderson Cancer Center
  • 2008-2012
    Paul Calabresi Clinical Oncology Award Program, Columbia University
  • 2009
    American Society of Hematology Clinical Research Training Institute, U. T. M. D. Anderson Cancer Center
  • 2009
    Lyndon B. Johnson Medical Oncology Service Fellow of the Year, U. T. M. D. Anderson Cancer Center
  • 2009
    The Janice Davis Singletary Fellowship for Lymphoma Research, U. T. M. D. Anderson Cancer Center

Selected Publications

  1. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 May 24.  View on PubMed
  2. Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL. Proceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma. Transplant Cell Ther. 2022 May 20.  View on PubMed
  3. D'Souza A, Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee CH, Mian H, Nathan S, Savani BN, Kumar SK, Qazilbash MH, Shah N. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 May 04.  View on PubMed
  4. Shah N, Mojebi A, Ayers D, Cope S, Dhanasiri S, Davies FE, Hari P, Patel P, Hege K, Dhanda D. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J Comp Eff Res. 2022 Apr 29.  View on PubMed
  5. Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, Natsuhara K, Martin T, Wolf J, Shah N, Wong SW. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022 Apr 12; 6(7):2045-2054.  View on PubMed
  6. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplant Cell Ther. 2022 Mar 17.  View on PubMed
  7. Banerjee R, Huang CY, Dunn L, Knoche J, Ryan C, Brassil K, Jackson L, Patel D, Lo M, Arora S, Wong SW, Wolf J, Martin Iii T, Dhruva A, Shah N. Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. JMIR Form Res. 2022 Mar 04; 6(3):e33701.  View on PubMed
  8. Delforge M, Shah N, Miguel JSF, Braverman J, Dhanda DS, Shi L, Guo S, Yu P, Liao W, Campbell TB, Munshi NC. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022 02 22; 6(4):1309-1318.  View on PubMed
  9. Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole DH, Stadtmauer E, Murray D. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer J. 2022 02 10; 12(2):27.  View on PubMed
  10. Vo K, Guan T, Banerjee R, Lo M, Young R, Shah N. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report. J Oncol Pharm Pract. 2022 Jan 27; 10781552221074269.  View on PubMed
  11. Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf J, Martin TG, Shah N, Wong SW. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021 12 14; 5(23):5344-5348.  View on PubMed
  12. Wong SW, Shah N, Ledergor G, Martin T, Wolf J, Shui AM, Huang CY, Martinez-Lopez J. Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. Front Oncol. 2021; 11:783703.  View on PubMed
  13. Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplant. 2022 Feb; 57(2):295-298.  View on PubMed
  14. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022 02; 28(2):83.e1-83.e9.  View on PubMed
  15. Tam AH, Jung Y, Young R, Huang CY, Wolf J, Shah N, Wong SW, Martin TG, Lo M. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. J Oncol Pharm Pract. 2021 Oct 14; 10781552211046911.  View on PubMed
  16. Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 01; 57(1):31-37.  View on PubMed
  17. Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021 08 17; 14(1):126.  View on PubMed
  18. Bigley AB, Spade S, Agha NH, Biswas S, Tang S, Malik MH, Dai L, Masoumi S, Patiño-Escobar B, Hale M, DiPierro G, Martell R, Hann B, Shah N, Wiita AP, Liu X. FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Blood Adv. 2021 08 10; 5(15):3021-3031.  View on PubMed
  19. Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, Shah N, Hari PN, D'Souza A. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer. 2021 11 15; 127(22):4233-4239.  View on PubMed
  20. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 08; 27(8):642-649.  View on PubMed

Go to UCSF Profiles, powered by CTSI